Results 21 to 30 of about 1,419,720 (263)

A COMPARATIVE ASSESSMENT OF THE EFFECT OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON CHANGES IN GALECTIN-3 AND MMP-1 FIBROSIS MARKERS IN PATIENTS WITH CHRONIC CARDIAC FAILURE COMBINED WITH TYPE 2 DIABETES MELLITUS WITH MANIFESTATIONS OF MYOCARDIUM DYSSYNCHRONY [PDF]

Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016
A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj   +1 more source

Aldosterone receptor antagonists: current perspectives and therapies

Vascular Health and Risk Management, 2013
Jason L Guichard, Donald Clark III, David A Calhoun, Mustafa I Ahmed University of Alabama at Birmingham, Department of Medicine, Division of Cardiovascular Disease, Vascular Biology and Hypertension Program, Birmingham, AL, USA Abstract: Aldosterone is ...
Guichard JL, Clark III D, Calhoun DA, Ahmed MI   +3 more
doaj   +1 more source

Mineralocorticoid Receptor Antagonists [PDF]

International Cardiovascular Forum Journal, 2019
Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
  +5 more sources

Mineralocorticoid Receptor Antagonists in Dialysis.

Am J Nephrol
Background: Aldosterone regulates genes controlling fluid and electrolyte balance through mineralocorticoid receptor (MR) activation. Sustained MR activation promotes inflammation, fibrosis, sodium retention, and myocardial remodeling. MR antagonists (MRAs) block aldosterone binding in the kidney, heart, and vasculature and are classified as steroidal ...
Elenjickal EJ, Mavrakanas TA.
europepmc   +4 more sources

Mineralocorticoid Receptor Antagonists in ESKD [PDF]

Clinical Journal of the American Society of Nephrology, 2020
There is an urgent need for interventions that reduce cardiovascular risks in patients with ESKD. Recently there has been considerable interest in whether blocking the effects of the mineralocorticoid aldosterone could be such an intervention.
Adhish, Agarwal, Alfred K, Cheung
openaire   +2 more sources

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: A systematic review and meta-analysis [PDF]

, 2016
Background: Hypertension and proteinuria are critically involved in the progression of chronic kidney disease. Despite treatment with renin angiotensin system inhibition, kidney function declines in many patients.
Townend, J. (Jonathan), Currie, G. (Gemma), Taylor, A.H.M. (Alison H. M.), Boesby, L. (Lene), Edwards, N.C. (Nicola C.), Lindhardt, M. (Morten), Preiss, D.J. (David J.), Fujita, T. (Toshiro), Meiracker, A.H. (Anton) van den, Mark, P.B. (Patrick B.), Oveisi, S. (Sonia), Delles, C. (Christian), Jardine, A.G. (Alan G.), Ohtsu, H. (Hiroshi), Rossing, K., Saklayen, M.G. (Mohammad G.), Ferro, C.J. (Charles J.)   +16 more
core   +5 more sources

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY

Рациональная фармакотерапия в кардиологии, 2017
The theory of chronic hyperactivation of neurohormonal systems, in particular, sympathoadrenal and renin-angiotensin-aldosterone, is the basis of modern concepts of the pathogenesis of heart failure. The medicinal blocking of these two systems has proved
O. M. Drapkina, D. U. Akasheva
doaj   +1 more source

Exclusion of the Locus for Autosomal Recessive Pseudohypoaldosteronism Type 1 from the Mineralocorticoid Receptor Gene Region on Human Chromosome 4q by Linkage Analysis. [PDF]

, 1995
Pseudohypoaldosteronism type 1 (PHA1) is an uncommon inherited disorder characterized by salt-wasting in infancy arising from target organ unresponsiveness to mineralocorticoids.
Hanukoglu, A., Gardiner, R.M., Bistritzer, T., Seckl, J., Chung, E., Kuhnle, U., Dillon, M., Gardiner, R. M., Hanukoglu, I., Rees, M., Thompson, R.   +10 more
core   +1 more source

Conformation of the Mineralocorticoid Receptor N-terminal Domain: Evidence for Induced and Stable Structure [PDF]

, 2010
The mineralocorticoid receptor (MR) binds the steroid hormones aldosterone and cortisol and has an important physiological role in the control of salt homeostasis.
Fischer, Katharina, Watt, Carolyn, McEwan, Iain Joseph, Nicholas C. Price, Kelly, S.M., Katharina Fischer, Price, N.C., McEwan, I. J., Watt, K., Fischer, K., Price, Nicholas C., Sharon M. Kelly, Kate Watt, Iain J. McEwan, Kelly, Sharon M.   +14 more
core   +1 more source

The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study. [PDF]

PLoS ONE, 2014
It has been suggested that mineralocorticoid receptor antagonists have direct cardioprotective properties, because these drugs reduce mortality in patients with heart failure.
T N A van den Berg, Jaap Deinum, Albert Bilos, A Rogier T Donders, Gerard A Rongen, Niels P Riksen   +5 more
doaj   +1 more source